RA Capital reports additional $11.88M sale of Vor Biopharma shares, reducing stake
VOR has more than doubled off its 52-week low of $2.622.
Summary
RA Capital Management, a significant institutional investor and director, reported selling an additional $11.88 million worth of Vor Biopharma shares, continuing a pattern of stake reduction.
Key Events · Ownership and Investor Activity · VOR
-
Significant Share Disposition
RA Capital Healthcare Fund, L.P. sold 737,989 shares of common stock in open market transactions between April 13 and April 15, 2026, for a total value of approximately $11.88 million.
-
Continued Stake Reduction
This filing marks a continuation of RA Capital's pattern of reducing its beneficial ownership in Vor Biopharma, following multiple prior Schedule 13D/A amendments reporting sales.
-
Remaining Ownership
Post-transactions, RA Capital Management, L.P. and its affiliates beneficially own 12,739,024 shares, representing 19.9% of the company's common stock.
Analysis · VOR · Life Sciences
This Schedule 13D/A updates RA Capital's beneficial ownership, disclosing further open market sales totaling approximately $11.88 million between April 13 and April 15, 2026. These transactions, also reported in a concurrent Form 4, represent a continued reduction in their stake, following multiple previous significant dispositions. While RA Capital remains a major shareholder, the ongoing sales by a key institutional investor and director could signal a lack of conviction or a strategic portfolio rebalancing. This activity is particularly notable given Vor Biopharma's recent $696 million net loss for 2025 and negative equity, and its recent $75 million private placement in March 2026. The continued reduction of a significant stake by a major investor, even as the company seeks to shore up its finances, could add selling pressure and raise questions about long-term confidence.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30.2% of the 2009 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.11%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VOR was trading at $15.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $762M. The 52-week trading range was $2.62 to $65.80. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.